Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 76

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 76
---
1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

In the second quarter of 2025, the Company continued to have favorable actual returns experience for Qelbree. As such, the Company changed its estimated provision for product returns based on the most recent experience. Provision for product returns related to prior year sales for the six months period ended June 30, 2025 is approximately 4% of net product sales primarily attributable to Qelbree. Provision for product returns related to prior year sales for the six months period ended June 30, 2024 was approximately 1% of net product sales. 

4. Investments 

Marketable SecuritiesUnrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):June 30, 2025December 31, 2024(unaudited)Corporate, U.S. government agency and municipal debt securitiesAmortized cost$378,087 $384,481 Gross unrealized gains16 89 Gross unrealized losses(218)(289)Total fair value$377,885 $384,281  As of June 30, 2025, all of the Company's unrestricted available-for-sale marketable securities have contractual maturities of one year or less.

As of June 30, 2025, there was no impairment due to credit loss on any available-for-sale marketable securities. 

11

5.    Fair Value of Financial Instruments

The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. Fair value hierarchy consists of the following three levels: •Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets. •Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves). •Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company's own assumptions. These are based on the best information available, including the Company